The financial terms of the current agreement have not been disclosed.
The contract covers initial activities in developing a controlled release formulation of an undisclosed compound using the drug delivery technology PolyActive, the company said.
The project is expected to progress into a full development, manufacturing and licensing agreement, if the evaluation is successful.
OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on their proprietary drug delivery technologies.